2023

• ADC Drug GQ1010, Co-Developed by Tyligand Bioscience and GeneQuantum Healthcare, was licensed to Pyridmid Biosciences, with upfront and milestone payment up to $ 1 billion
• Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist
• Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222
• Tyligand Bioscience Receives U.S. FDA Orphan Drug Designation for TSN084 for the Treatment of Acute Myeloid Leukemia
• Tyligand Bioscience Secures Multi-Million Dollar Series A+ Funding to Accelerate Clinical trials for Innovative Small Molecule Cancer Treatment